Gerd supports Apollo and its portfolio as Venture Partner
He has more than 20 years of experience in the pharma and biotech industry R&D and previously led R&D at Jerini AG and OryzonGenomics. Oryzon develops novel therapeutics based on epigenetics
Gerd has a broad experience in the development of small molecules, peptides and peptidomimetics covering a wide range of therapeutic areas and therefore can provide highly valuable guidance in shaping R&D
Before consulting international biotech companies, he received his PhD in organic chemistry from University of Konstanz
Gerd supports Apollo and its portfolio as Venture Partner
He has more than 20 years of experience in the pharma and biotech industry R&D and previously led R&D at Jerini AG and OryzonGenomics. Oryzon develops novel therapeutics based on epigenetics
Gerd has a broad experience in the development of small molecules, peptides and peptidomimetics covering a wide range of therapeutic areas and therefore can provide highly valuable guidance in shaping R&D
Before consulting international biotech companies, he received his PhD in organic chemistry from University of Konstanz
